Mezavant (Mesalazine)

Mesalazine works locally in the intestinal lining where it blocks cyclooxygenase and lipoxygenase enzymes. This inhibition reduces the production of prostaglandins and leukotrienes, key mediators of inflammation, thereby decreasing mucosal irritation and promoting healing.

The dose of Mezavant is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. Healthcare providers determine the appropriate strength and frequency, and patients should follow the prescribed regimen exactly.

Safety data for mesalazine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare professional.

To request Mezavant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant belongs to the aminosalicylate class, which is generally used for mild‑to‑moderate ulcerative colitis. Compared with biologic agents, it has a more favorable safety profile but may be less effective in severe disease. It is often used before escalating to immunomodulators or biologics.

Mezavant tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct light, and ensure the packaging remains tightly closed until use.

Mezavant is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, usually with or without food, as directed by their prescriber. The tablet should not be crushed or chewed unless specifically advised.

The most serious adverse events include severe allergic reactions such as anaphylaxis, kidney inflammation (interstitial nephritis), and blood disorders like neutropenia or agranulocytosis. Patients should seek immediate medical attention if they experience symptoms such as rash, fever, unexplained bruising, or changes in urine output.

Mezavant is contraindicated in individuals with a known hypersensitivity to mesalazine or any component of the tablet. It should also be avoided in patients with severe renal or hepatic impairment unless specifically directed by a specialist, and in those with a history of severe sulfonamide allergy.